Menu Search
Equities

Formycon AG

FYBX:GER

Formycon AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)46.85
  • Today's Change0.35 / 0.75%
  • Shares traded6.07k
  • 1 Year change-23.94%
  • Beta0.6291
Data delayed at least 15 minutes, as of Nov 22 2024 16:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform7
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The 11 analysts offering 12 month price targets for Formycon AG have a median target of 89.00, with a high estimate of 130.00 and a low estimate of 63.00. The median estimate represents a 91.40% increase from the last price of 46.50.
High179.6%130.00
Med91.4%89.00
Low35.5%63.00

Earnings history & estimates in EUR

Formycon AG reported annual 2023 earnings of 4.76 per share on Apr 12, 2024.
Average growth rate-52.36%
More ▼

Revenue history & estimates in EUR

Formycon AG had 2nd quarter 2024 revenues of 9.19m. This missed the 14.00m estimate of the one analyst following the company. The same period last year the company did not report revenues.
Average growth rate+39.61%
Formycon AG had revenues for the full year 2023 of 77.70m. This was 82.83% above the prior year's results.
Average growth rate+27.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.